Cathay Capital, a private equity firm, led a $50m Series D funding round in TISSIUM, a developer of biodegradable sealants and adhesives for surgical-wound closure, with participation from Fonds Stratégique des Transitions, Merieux Developpement, Credit Mutuel Innovation, and Sofinnova Partners. "With the closing of our Series D financing round, TISSIUM is well-positioned to finance the commercialization of its first products. This funding significantly bolsters our ability to move with speed towards our goal of enhancing tissue reconstruction for patients. We look forward to continuing our work to bring innovation in the space and develop products that make a difference in patients’ lives,” Christophe Bancel, TISSIUM CEO.